Last week the 6th edition of the TIM (TNO gastroIntestinal Model) User Group meeting took place in Amsterdam. The 2-day event was extraordinary for various reasons. First of all, we welcomed 50 guests from all over the globe, the highest attendance since the start of the event in 2009.
This year’s edition was also an anniversary, since it was 25 years ago that Rob Havenaar and Mans Minekus started to develop the first prototype of an in vitro gastro intestinal model, soon to be known as TNO’s Intestine Model, TIM.
And we proudly introduced our new generation TIM system, which is designed as an easy-to-use, robustly engineered, smart and highly predictive in vitro model.
Last, but certainly not least, the program had a great line-up of reputable speakers from both academia and industry, presenting their latest results in both pharmaceutical and food in vitro gastro-intestinal research.
Both the setting and the informal atmosphere in which the event took place contributed to an open stimulating exchange of ideas, experiences and results. The new TIM model was received with great enthusiasm and the festive launch concluded a highly successful event.
All in all, we are proud to be part of the community of TIM Users and we invite you to join in.
For more information, please contact us: email@example.com.
On behalf of an international REACH consortium, Triskelion will be undertaking its biggest ever assignment, namely an impressive study package aimed at guaranteeing human safety. The performance of these studies has been made compulsory by the European legislation on chemicals (REACH). This study package comprises two Prenatal Developmental Toxicity studies (OECD 414) with prior Dose Range Finding studies and an Extended One Generation Reproduction Toxicity Study (EOGRTS; OECD 443). The studies are worth a total of some two million euros.
Expertise, flexibility and planning are the primary reasons why Triskelion has been selected by the consortium of 18 global players to carry out this complex package of studies. Triskelion has a reputation for its excellent qualities in the field of inhalation toxicology and is convinced that it can complete this study package capably and on time. The timeline for the whole study package of around 19 months presents a fantastic logistical challenge.
Triskelion – one of the 24 companies in the portfolio of First Dutch Innovations – is a growing Contract Research Organization (CRO) with around 200 employees serving clients from all over the world. Triskelion is the CRO for complex study packages and is active in the Chemical, Pharmaceutical, Food and Biotech industries. Specialization in multidisciplinary projects, consultancy skills, knowledge and personal attention all go towards creating client-specific study protocols and reliable project management.
For more information please feel free to contact Yvette Estourgie:
Phone number: +31 88 866 2727
E-mail address: mailto:firstname.lastname@example.org
We are proud to present an article based on Waters business case regarding Triskelion’s analytical expertise (LC-MS).
Article title: “A Leading CRO’s Customer Focus Leads to Improvements in Quality and Productivity”
Please have a look at the entire article.
First Dutch Innovations, the new name for TNO Companies bv, will launch today its operations. The Consumer and Market Authority (ACM) recently granted approval for the acquisition of TNO Companies by Peter Goedvolk/First Dutch. TNO will retain a minority stake. First Dutch Innovations has appointed Gina van der Werf Chief Executive Officer.
First Dutch Innovations is committed to the develop and grow innovative companies in the main focus areas: Life Sciences, Sustainable Energy and TIC (Testing, Inspection and Certification) markets enabling innovation in the Netherlands in a sustainable way. Moreover, the company has the explicit goal to increase employment in the Dutch innovative sector.
Gina van der Werf, CEO of First Dutch Innovations: “At First Dutch Innovations innovative power and entrepreneurship converge. We are planning to bring several new valorisations to market each year and to further develop existing companies within the Innovations concept. In a time when many Dutch companies are bought by foreign companies, it is crucial to continue the development of knowledge and bring valorisations to the Dutch market.”
First Dutch Innovations will work in close collaboration with TNO and the other knowledge based institutions in the Netherlands to create a central platform in which knowledge development and entrepreneurship can be merged.
First Dutch Innovations currently has 24 innovative companies with approximately 900 employees. This provides the basis for the expansion of the platform with more innovative companies within the focus areas. First Dutch Innovations will continue to look for enterprising disruptors that fit this profile.
More information: www.firstdutchinnovations.nl.
Proudly we would like to share an article of Clermont Ferrand which gives you a great overview of our TNO gastroIntestinal Model (TIM).
The TIM-1 and tiny-TIM systems simulate the dynamic conditions in the stomach and small intestine, whereas the TIM-2 system simulates the large intestine.
Curious to learn more about our TIM systems? Please do not hesitate to contact us: email@example.com.